Skip to main content

Table 4 Logistic regression models for pCR with p values, odds ratio, and confidence intervals

From: Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

miRNAs

Patients

All BC patients

HER2-positive patients

TNBC patients

Model

Univariate

Multivariate

Univariate

Multivariate

Univariate

Multivariate

miR-20a

All

_

_

_

_

_

_

In PM

_

_

_

_

_

_

In PMCb

p = 0.020

1.39 (1.05–1.84)

p = 0.019

1.41 (1.06–1.89)

_

_

_

_

miR-27b

All

_

_

p = 0.035

1.30 (1.02–1.65)

p = 0.050

1.28 (1.00–1.63)

_

_

In PM

_

_

_

_

_

_

In PMCb

p = 0.038

1.27 (1.01–1.59)

p = 0.030

1.30 (1.03–1.64)

_

_

_

_

miR-99b

All

p = 0.103

1.14 (0.97–1.34)

p = 0.039

1.19 (1.01–1.41)

_

_

_

_

In PM

_

_

_

_

_

_

in PMCb

_

_

_

_

_

_

miR-155

All

p = 0.002

1.25 (1.08–1.44)

p = 0.003

1.24 (1.08–1.44)

p = 0.049

1.24 (1.00–1.53)

p = 0.035

1.26 (1.02–1.56)

p = 0.013

1.29 (1.05–1.57)

p = 0.018

1.29 (1.04–1.58)

In PM

p = 0.033

1.26 (1.02–1.55)

p = 0.049

1.24 (1.00–1.53)

_

_

_

_

In PMCb

p = 0.032

1.24 (1.02–1.51)

p = 0.023

1.27 (1.03–1.55)

_

_

_

_

miR-193b

All

p = 0.039

1.13 (1.01–1.26)

p = 0.055

1.12 (1.00–1.26)

p = 0.010

1.26 (1.06–1.50)

p = 0.012

1.26 (1.05–1.51)

_

_

In PM

_

_

_

_

_

_

In PMCb

_

_

_

_

_

_

miR-301

All

p = 0.002

1.25 (1.08–1.44)

p = 0.001

1.27 (1.10–1.46)

p = 0.013

1.30 (1.06–1.60)

p = 0.011

1.32 (1.07–1.64)

_

_

In PM

p = 0.040

1.22 (1.01–1.48)

p = 0.028

1.25 (1.02–1.52)

_

_

_

_

In PMCb

p = 0.020

1.28 (1.04–1.57)

p = 0.022

1.29 (1.04–1.6)

p = 0.012

1.53 (1.10–2.12)

p = 0.016

1.51 (1.08–2..12)

_

_

miR-365

All

_

_

_

_

_

_

In PM

_

_

p = 0.052

1.35 (1.00–1.81)

p = 0.038

1.39 (1.02–1.90)

_

_

In PMCb

_

_

_

_

_

_

miR-423-5p

All

p = 0.048

1.19 (1.00–1.42)

p = 0.064

1.18 (0.99–1.41)

_

_

_

_

In PM

_

_

_

_

_

_

In PMCb

_

_

_

_

_

_

miR-511

All

_

_

_

_

_

_

In PM

_

_

_

_

_

_

In PMCb

_

_

_

_

p = 0.239

0.90 (0.76–1.07)

p = 0.043

0.78 (0.62–0.99)

miR-628-5p

All

_

_

_

_

p = 0.024

0.81 (0.67–0.97)

p = 0.017

0.79 (0.65–0.96)

In PM

_

_

_

_

_

_

In PMCb

_

_

_

_

_

_

miR-660

All

_

_

p = 0.044

1.35 (1.01–1.80)

p = 0.027

1.40 (1.04–1.89)

_

_

In PM

_

_

_

_

_

_

In PMCb

_

_

_

_

_

_

miR-891a

All

p = 0.063

1.07 (1.00–1.15)

p = 0.036

1.08 (1.01–1.16)

_

_

_

_

In PM

_

_

_

_

_

_

In PMCb

_

_

_

_

_

_

  1. Cells filled with “-” denote insignificant miRNA contributions to the models. MiRNAs which do not show significant contributions in any population were omitted. For each miRNA variable and each patient group, a univariate as well as a multivariate model with the covariables of age, nodal status, tumor size, and grading were calculated
  2. The odds ratio with the 95% confidence interval and the associated Wald p value for the miRNAs are presented
  3. PM non-carboplatin treatment arm, PMCb carboplatin treatment arm